2-[[[2-[(HYDROXYACETYL)AMINO]-4-PYRIDINYL]METHYL]THIO]-N-[4-(TRIFLUOROMETHOXY)PHENYL]-3-PYRIDINECARBOXAMIDE BENZENE- SULFONATE, CRYSTALS OF SAME, POLYMORPHS THEREOF, AND PROCESSES FOR PRODUCTION THEREOF
申请人:Santen Pharmaceutical Co., Ltd
公开号:EP2455368A1
公开(公告)日:2012-05-23
In the course of developing 2-[[[2 - [(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- N -[4 -(trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide(compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly. For solving these problems, we made examination focusing on the kind of the salt and, as a result, found that 1) benzenesulfonate of compound A does not decompose by light, humidity and other factors in a 1-week preliminary stability test (severe test), and has no problem in its storage stability, 2) a method of selectively producing two kinds of crystal forms of benzenesulfonate of compound A, and that 3) no mineral deposition in the stomach is observed even after a 4-week repeated oral administration.
在开发 2-[[[2-[(羟基乙酰)氨基]-4-吡啶基]甲基]硫]-N-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺(化合物 A)的过程中,存在多种问题:1)化合物 A 或其盐很难重结晶,盐的种类不同,贮存稳定性也有很大差异,很难获得贮存稳定性极佳的化合物 A 盐;2)在化合物 A 的结晶过程中,很难控制晶体的多态性;3)反复口服化合物 A(游离体)会导致矿物质在胃内沉积。为了解决这些问题,我们对盐的种类进行了研究,结果发现:1)化合物 A 的苯磺酸盐在为期 1 周的初步稳定性试验(严酷试验)中不受光照、湿度和其他因素的影响而分解,在贮存稳定性方面也没有问题;2)一种选择性生产化合物 A 的苯磺酸盐的两种晶体形态的方法;3)即使反复口服 4 周,也不会观察到胃中有矿物质沉积。